[Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization].
D000328:Adult; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood / Q000627:therapeutic use*; D002951:Citrates / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006909:Hydroxyproline / Q000378:metabolism*; D006962:Hyperparathyroidism, Secondary / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010758:Phosphorus / Q000097:blood; D006435:Renal Dialysis; D012964:Sodium / Q000627:therapeutic use
D002951:Citrates; D004338:Drug Combinations; D010758:Phosphorus; D000536:Aluminum Hydroxide; D012964:Sodium; D006909:Hydroxyproline; D002118:Calcium
Hydroxyprolin im Dialysat als Parameter des sekundären Hyperparathyreoidismus, Beeinflussung durch Phosphatsenkung und Alkalisierung.